Spiderboy and GFP,
The artifact was proven to be caused by sample fixation. The FDA just chose to use that doubt as a "cause" for dismissal. If COR could play ball (bribery-wise) with the FDA, the explanation for the artifact issue would have sufficed.
We now know that CX-717 has an effect on ADHD and RD. Likely, it has many other undiscovered/untested benefits to a human, with little or no side effects. This is CX-717. They have it and it works today. Future molecules are likely to be more potent with even less side effects end patent life out to 2028.
Once the financial future questions are resolved, COR could be a home run folks. Personally, I would like a buyout by Schering with the option of getting cash or Schering stock for my COR shares.
If Ampakines had some financial/manufacturing and marketing muscle behind them, WOW! This stuff could be manna from heaven for the next quarter century.
MF4
News 
Market Data 
Discover 
AI
